FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia
Acute Myeloid Leukemia
DRUG: FLAG+IDA
Complete remission rate, duration of complete remission, toxicities, 06/2008
progression-free survival, overall survival, 06/2008
- The feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease-free survival, and overall survival.